Genetic studies in complex disease
Rosendaal, F.R.; Reitsma, P.H.; Mollica, L.; Lane, D.A.; Margaglione, M.; Merini, P.;
Ardissino, D.

Citation
Rosendaal, F. R., Reitsma, P. H., Mollica, L., Lane, D. A., Margaglione, M., Merini, P., &
Haemostasis, 2(2), 342-345. Retrieved from https://hdl.handle.net/1887/5098

Version: Not Applicable (or Unknown)
License:
Downloaded from: https://hdl.handle.net/1887/5098

Note: To cite this publication please use the final published version (if applicable).
Genetic studies in complex disease

F. R. ROSENDAAL* and P. H. REITSMA†
*Departments of Clinical Epidemiology and Hematology, Leiden University Medical Center, Leiden, the Netherlands; and †Laboratory for Experimental Internal Medicine, Academic Medical Center, Amsterdam, the Netherlands.


While we do not wish to restate the points in the debate with Souto [1] concerning various approaches to find novel genetic risk factors for thrombosis, we wish to comment on one statement in Souto’s interesting contribution. He rightly points out that only three genetic factors that were recently discovered have been consistently associated with venous thrombotic risk: ABO blood group, factor (F)V Leiden, and prothrombin 20210A. He then states that FV Leiden is particularly illustrative since it was first found through a linkage study. This is not true: FV Leiden was found, following the report on APC-resistance by Dahlbäck [2], nearly simultaneously by three groups, who all used either mixing experiments or direct sequencing and genotyping of the candidate gene (FV) [3–5]. In our paper, we did report on linkage in a single pedigree as a confirmatory experiment [3]. History has it that none of the six established genetic risk factors for venous thrombosis, where we add deficiencies to protein C, protein S and antithrombin to the list, has been found through linkage. We know, since we were there.

References

Correspondence: F.R. Rosendaal, Clinical Epidemiology, C9-P, Leiden University Medical Center, P.O. Box 9600, NL-2300 RC Leiden, the Netherlands.
Tel.: +31 71 5264037; fax: +31 71 5266994; e-mail: f.r.rosendaal@lumc.nl


L. MOLLICA and D. A. LANE
Imperial College London, Hammersmith Hospital Campus, London, UK


In their articles as part of the Debate: Genetic studies in complex disease, Souto and Rosendaal [1,2] make the respective cases for linkage and association studies. It is impossible to disagree with the positive points made about these approaches, which have produced many landmark discoveries. The enthusiasm for these types of study has been facilitated by progress in molecular genetics, which has considerably simplified the detection of various genetic variants. However, despite the respective strengths of linkage and association studies outlined by Souto and Rosendaal, their widespread use has not always been accompanied by proportionate progress. Lack of reproducibility is certainly one of the most dominant outcomes of their application to the genetic basis of many common complex diseases. The field of atherothrombotic disease is no exception, and is flooded by studies reporting inconsistent and contradictory results. Not surprisingly, this has left a legacy of considerable uncertainty [3,4]. Furthermore, simple application of both approaches will always provide an incomplete picture and give only a preliminary indication of the risk associated with a given genotype. Any causative relationship between genotype and disease must be mediated through a phenotype, and this must be fully understood before genetic risks can be applied clinically.

There are several well-rehearsed potential explanations for the inconsistent literature on genetic risk factors, including poor study design, population stratification and excessive subgroup analysis. Perhaps most important, however, is that the phenotype effect of a given genotype is likely to be small in complex diseases. Given that the effect of a phenotype on disease is often

Correspondence: David A. Lane, Imperial College London, Hammersmith Hospital Campus, London W12 ONN, UK.
Tel.: +44 (0) 20 8388 2295; fax: +44 (0) 20 8388 2296; e-mail: d.lane@imperialcollege.ac.uk

© 2004 International Society on Thrombosis and Haemostasis
difficult to demonstrate, the study of a genotype cannot be
equated to make this task quantitatively easier. The size of a
study is the major determinant of its power. This becomes a
critical issue when searching for small increased risk, ~20% or
less. Most studies of the risks of haemostatic genetic risk factors
in thrombotic disease have been too small to be informative.
Conclusions from small studies, especially those failing to show
consistent relationships between genotype, phenotype and dis-
ease, should be considered with great circumspection. A recent
example of how the outcome of a large study (4484 patients and
5757 controls) can overturn conclusions from small studies (~100 patients) is provided elsewhere [5–7]. Inevitably, large
study design cannot always be optimal [8], but there is now
growing acceptance that they alone provide the increased power
that is needed to clarify the role of genes in common disorders
such as atherothrombotic disease [9]. Pooling of patients into
centrally organized sample and data collections will be neces-
sary to obtain the population size required for these studies.
Although this will remove independent research opportunity
from investigators with small and medium-sized patient co-
horts, it is currently the only feasible approach for tackling the
issue of genetic predisposition to common diseases. An exam-
ple of such an initiative is the Type 1 Diabetes Genetics
Consortium (T1DGC), which has been developed to organize
international efforts to identify genes that determine an indi-
vidual’s risk of type 1 diabetes (http://www.t1dgc.org).

Although there is current difficulty in drawing firm conclu-
sions from inconsistent results in atherothrombotic diseases,
this should neither discourage the search for genetic predis-
position to disease, nor imply that molecular genetics is incap-
able of efficiently approaching diseases with a genetic and
environmental complex determinism. Rather, it should provide
us a more critical view with which to interpret the literature on
genetic risk and from which we can progress.

References
1 Souto JC. Genetic studies in complex disease: the case pro linkage
2 Rosendaal FR. Genetic studies in complex disease: the case pro associa-
3 Lane DA, Grant PJ. Role of hemostatic gene polymorphisms in venous
4 Simmonds RE, Hermida J, Rezende SM, Lane DA. Haemostatic genetic
5 Keaveny B, Parish S, Palmer A, Clark S, Youngman L, Danesh J,
McKenzie C, Delepine M, Lathrop M, Petru R, Collins R. International
Studies of Infarct Survival (ISIS) Collaborators. Large-scale evidence that
the cardiotoxicity of smoking is not significantly modified by the apolipo-
6 Humphries SE, Talmud PJ, Hawe E, Bolla M, Day IN, Miller GI.
Apolipoprotein E4 and coronary heart disease in middle-aged men
7 Stengard JH, Kardia S, Tervahauta M, Ehnholm C, Nissinen A, Sing CF.
Utility of the predictors of coronary heart disease mortality in a longi-
tudinal study of elderly Finnish men aged 65–84 years is dependent
on context defined by Apo E genotype and area of residence. Clin Genet
8 Humphries SE, Hawe E, Sukhdil B, Miller GI, Talmud PJ. In search of
9 Keaveny B, Parish S, Lathrop M, Petru R, Collins R. Large-scale evidence
that the cardiotoxicity of smoking is not significantly modified by the
apoliprotein E epsilon2/epsilon3/epsilon4 genotype. Author reply.

M. MARGAGLIONE
Unita’ di Aterosclerosi e Trombosi, I.R.C.C.S. ‘Casa Sollievo della
Sofferenza’, S. Giovanni Rotondo; and Genetic Medica, Universita’ di
Foggia, Italy

To cite this article: Margaglione M. Forum on genetic studies in

See also Souto JC. Genetic studies in complex disease: the case pro
linkage. J Thromb Haemost 2003; 1: 1676–8; Rosendaal FR. Genetic
studies in complex disease: the case pro association studies. J Thromb

The importance of inheritance in human diseases was recog-
nized nearly a century ago. Since then, two contrasting points of
view have prevailed, the ‘Mendelist and the biometricist view of
the world’ [1]. Mendelian diseases are traits in which differ-
ences are due to different alleles at a single (or few) locus.
Linkage analysis has had a remarkable role in leading to the
identification of genes responsible for mendelian diseases.
However, it has been proven to be a far less reliable tool when
applied to non-mendelian (also known as multifactorial or
complex) diseases. On the other hand, complex diseases are
at the cross-roads between inherited and non-inherited factors,
and are the result of the contribution of many different genes
to the total variability, with no particular gene having a large
effect. In complex diseases, association studies have found
hundreds of potential associations with common gene variants,
no matter whether the gene variants identified directly affect
the risk or are simply a marker. Unfortunately, association studies
have shown a long series of false-positive results and very few
associations have been consistently replicated [2].

Two different working models underlie the different pro-
cedures for studying the contribution of genes to diseases [3,4].
On one hand, the probability of sharing a segment of a chromo-
some among affected individuals, linkage analysis, leads to the
possibility that a specific region harbors one (or more) pathogenic
gene(s). Then, one has to demonstrate the biological plausibility
of the identified gene (reverse genetics). On the other hand, in
association studies we need to have an a priori hypothesis on the
role of the investigated gene (forward genetics). As far as
venous thromboembolism is concerned, the latter approach
gave remarkable results leading to the identification of impor-
tant risk factors, such as the factor V Leiden and the factor II
A20210 allele [5,6]. It is not unlikely that future association

Correspondence: M. Margaglione, Unita’ di Aterosclerosi e Trombosi,
I.R.C.C.S. ‘Casa Sollievo della Sofferenza’, S. Giovanni Rotondo; and
Genetica Medica, Università di Foggia, Italy.
Tel.: +39 0881 733842; fax: +39 0881 732188; e-mail: ate.tro@operapadrepio.it

© 2004 International Society on Thrombosis and Haemostasis
studies may be able to find new gene variants affecting susceptibility to venous or arterial thrombosis. Linkage analysis showed, at the best, a series of loci that could explain a portion of the interindividual variability of intermediate phenotypes [7,8]. However, we must look ahead. The analysis of the genome sequence revealed a high percentage of annotated genes with unknown functions (42%). The percentage was higher if one also considers hypothetical genes (59%) [9]. In other words, we know of the existence of a huge number of genes, but for most of them we ignore what they do. We need to know their function. It is conceivable that a number of new genes may be functional for normal hemostasis and allelic variants may play a significant role in common, complex diseases, such as atherosclerosis, venous and arterial thrombosis. In the meanwhile, we have to rethink our approach in the search for the genetic component of complex diseases. As we are facing a spectacular and rapid advance of technology, the association of computational and molecular technology may offer new models to approach this search. An example of this is the identification of a new gene associated with common forms of ischemic stroke [10]. The deCODE genetics of Iceland has identified as a susceptibility locus the gene encoding phosphodiesterase 4D (PDE4D) by merging linkage analysis and association studies, investigating a high number of individuals and adopting strict epidemiological criteria. Traditional linkage analysis and association studies have been successful in locating loci and identifying functional variants, but they are probably coming at an end.

It is conceivable that in the future the identification of genes affecting susceptibility to complex diseases will require new methods of population-based genetic investigation taking advantage of high-throughput genomic methods and broad community collaboration.

References
6 Poort SR, Rosendaal FR, Reitsma PH, Bertina RM. A common genetic variation in the 3'-untranslated region of the prothrombin gene is associated with elevated plasma prothrombin levels and an increase in venous thrombosis. Blood 1996; 88: 3698–703.

P. MERLINI and D. ARDISSINO


Since the introduction of user-friendly and high-throughput techniques for performing genetic studies in complex diseases, a large number of (published and unpublished) studies have been carried out in an attempt to find polymorphisms or variants of putative genes and establish their relationships with myocardial infarction.

However, as none of the single nucleotide polymorphisms (SNPs) of genes encoding proteins involved in atherothrombosis has yet been consistently associated with an increased or decreased risk of myocardial infarction or stroke, it is not surprising that doubts are beginning to arise as to whether the main reason for this lack of success is methodological [1]. Are we using an inadequate tool? Association studies are appealingly quick and cheap, have successfully identified traditional risk factors and, Rosendaal points out [2], have been extensively used in genetic research—but extensively is not the same as successfully. On the other hand, although linkage studies have been successfully used in the study of monogenic diseases, their value in identifying new culprit genes associated with myocardial infarction has not yet been proved.

Rosendaal makes a very good point that should not be forgotten: it is not a question of deciding between association and linkage studies, but between ‘proof of concept’ studies and ‘fishing expeditions’.

We know quite a lot about the pathophysiology of myocardial infarction, and have identified a number of factors that are almost certainly involved, such as inflammation, thrombosis and lipid metabolisms. However, the proteins involved in these mechanisms are encoded by thousands of genes, and we still do not know enough about other mechanisms involving an equally large number of genes. The result is that, although there are many pathophysiological candidates, we need to identify the most important and complete our understanding of them. Positional candidates are welcome. Linkage studies can help us to focus on the most likely regions and thus enable us to concentrate on what our knowledge indicates as being the most likely candidates; the epidemiological relevance of such candidates can then be confirmed (or not) by association studies. Linkage and association approaches are therefore not mutually exclusive but complementary, and have been recently integrated.

Correspondence: D. Ardissino.
E-mail: ardis001@planet.it
with other approaches such as gene expression profiling (transcriptome analysis) and proteomics. By studying the tissues or cells (atherosclerotic plaques, circulating blood cells) directly involved in both normal and diseased states, as well as at different time points during the course of disease, we can identify new candidates deserving further investigation in functional and epidemiological studies; furthermore, the availability of new databases correlating gene function and known SNPs could lead to a major breakthrough. In our opinion, we are now beginning to come out of the fog. Rather than being simply a means of finding genes, genetic studies are much more complex and require the integration of different methodologies and approaches, in the same way that the development of a new drug does not depend on Phase III trials alone but has to go through many other stages before reaching the clinical arena.

References